Sarepta Therapeutics (SRPT) has caught the attention of investors after shares rose nearly 2% in recent trading. The move comes as the biotech sector shows mixed results and puts a spotlight on ...
Sarepta's Q3 loss and the failure of its key DMD study sent shares tumbling, clouding hopes for its PMO therapies and gene therapy Elevidys.
The post Market Analysis: Nov 4th, 2025 appeared first on Stock Target Advisor.
Hosted on MSN
Sarepta falls -30.9%
Sarepta (SRPT) is down -30.9%, or -$7.56 to $16.89. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback